Skip to content
In Stock Abilify
Antipsychotics

Abilify

Adults with schizophrenia or bipolar I disorder may be prescribed Abilify tablets to reduce psychotic symptoms and stabilise mood. Abilify contains aripiprazole, an atypical antipsychotic that…

Guaranteed quality Original product
Delivery: from 4 days Discreet shipping
24/7 Support Always available
Active ingredient: Aripiprazole
Select dosage:
Select pack Package Per unit Price
$ 3.12 $ 186.90
$ 2.69 $ 280.35 $ 242.08 Save 14%
Free Regular Delivery $ 2.26 $ 560.70 $ 407.62 Save 27%
Free Express Delivery $ 2.13 $ 841.05 $ 574.94 Save 32%
Best value Free Express Delivery $ 2.06 $ 1,121.40 $ 740.48 Save 34%
$ 5.87 $ 176.22
$ 4.15 $ 352.44 $ 249.20 Save 29%
$ 3.58 $ 528.66 $ 322.18 Save 39%
Free Regular Delivery $ 3.26 $ 704.88 $ 391.60 Save 44%
Free Express Delivery $ 3.01 $ 1,057.32 $ 541.12 Save 49%
Free Express Delivery $ 2.81 $ 1,585.98 $ 758.28 Save 52%
Best value Free Express Delivery $ 2.69 $ 2,114.64 $ 968.32 Save 54%
$ 6.29 $ 188.68
$ 4.45 $ 377.36 $ 267.00 Save 29%
$ 3.84 $ 566.04 $ 345.32 Save 39%
Free Regular Delivery $ 3.50 $ 754.72 $ 420.08 Save 44%
Free Express Delivery $ 3.20 $ 1,132.08 $ 576.72 Save 49%
Free Express Delivery $ 3.01 $ 1,698.12 $ 811.68 Save 52%
Best value Free Express Delivery $ 2.90 $ 2,264.16 $ 1,044.86 Save 54%
$ 4.92 $ 147.74
$ 3.26 $ 295.48 $ 195.80 Save 34%
$ 2.83 $ 443.22 $ 254.54 Save 43%
$ 2.40 $ 590.96 $ 288.36 Save 51%
Best value Free Regular Delivery $ 2.00 $ 886.44 $ 359.56 Save 59%

Free delivery on orders from $ 356.00, free express delivery from $ 534.00

Secure payment methods:
VISA AMEX JCB DISCOVER

Adults with schizophrenia or bipolar I disorder may be prescribed Abilify tablets to reduce psychotic symptoms and stabilise mood. Abilify contains aripiprazole, an atypical antipsychotic that modulates dopamine and serotonin signalling.

Product information

Abilify is an atypical antipsychotic medication containing aripiprazole. It is used in psychiatric treatment plans for schizophrenia and bipolar I disorder.

Ingredients

Abilify tablets contain aripiprazole, which belongs to the atypical antipsychotic group.

Therapeutic indications

Aripiprazole is used in psychiatric treatment plans for schizophrenia and bipolar I disorder. The therapeutic aim is not simply sedation. Clinicians assess whether hallucinations, delusions, thought disorder, agitation, impulsivity, sleep disruption, or manic behaviour are becoming less severe.

Schizophrenia

For schizophrenia, aripiprazole may be used during an acute episode and during maintenance treatment after symptoms have improved. Maintenance therapy aims to reduce relapse risk and preserve day-to-day functioning. Treatment response is assessed through symptoms, sleep, communication, self-care, substance use, and the person’s ability to manage ordinary activities.

Bipolar I disorder

In bipolar I disorder, aripiprazole is used for manic or mixed episodes and may continue during maintenance treatment when clinically appropriate. Mania can involve unusually elevated or irritable mood, reduced need for sleep, rapid speech, racing thoughts, impulsive decisions, and increased activity.

A psychiatrist may review sleep, spending, risk-taking, irritability, and the return of depressive symptoms. Aripiprazole is not a universal treatment for every type of depression, anxiety disorder, or mood fluctuation.

Clinical use Main treatment goal Monitoring focus
Schizophrenia Reduce psychosis and support relapse prevention Hallucinations, delusions, movement symptoms, metabolic health
Bipolar I mania or mixed episodes Reduce manic activation and improve behavioural control Sleep, impulsivity, agitation, mood changes, akathisia

The American Psychiatric Association recommends structured assessment of symptoms, functioning, adverse effects, and adherence when antipsychotic treatment is reviewed.[2] A person can feel calmer before delusions or disorganised thinking have fully improved, so early improvement does not always mean the illness is completely controlled.

Directions for use

  • Dose: The dose of Abilify tablets is selected individually for each person and adjusted as part of the prescribed psychiatric treatment plan.
  • How to take it: Take Abilify by mouth as a tablet according to the prescribed schedule. Treatment may continue during an acute episode and as maintenance therapy after symptoms improve.
  • Ongoing treatment: Continue Abilify for the duration prescribed by the treating clinician. If a tablet is missed, do not automatically double the next dose; repeated missed doses require advice from the treating service.

When not to use it

Specific conditions require careful clinical assessment:

  • Dementia-related psychosis in an older adult.
  • Previous neuroleptic malignant syndrome.
  • Seizure disorder or a condition that lowers the seizure threshold.
  • Diabetes, prediabetes, obesity, or a strong family history of diabetes.
  • Significant cardiovascular disease, fainting, or rhythm abnormalities.
  • A history of severe impulse-control problems.
  • Pregnancy or breastfeeding.
  • Difficulty swallowing or a high risk of aspiration.

Carbamazepine is a strong CYP3A4 inducer and can substantially reduce aripiprazole exposure. Strong CYP2D6 inhibitors include fluoxetine and paroxetine; dose adjustment may be required when they are combined with aripiprazole. Posaconazole and other strong CYP3A4 inhibitors can also increase exposure.

The TGA product information describes dose adjustment requirements when aripiprazole is used with strong CYP2D6 or CYP3A4 inhibitors and inducers.[3]

When this is not for you

Abilify is not suitable for everyone. This medication is not for you if you have had a serious allergic reaction to aripiprazole or another ingredient in the prescribed tablet. Swelling of the face or throat, breathing difficulty, widespread rash, or collapse requires emergency treatment.

Alcohol can increase dizziness, impaired judgement, and sedation. Driving or operating machinery requires caution until the individual response is clear. Heat exposure and dehydration can worsen dizziness or fainting, especially in people who already have low blood pressure.

Unwanted effects

Aripiprazole can cause adverse effects even when it improves psychiatric symptoms. The most useful review separates common tolerability problems from reactions that need prompt medical assessment.

Common or clinically recognised reactions include:

  • Akathisia, which feels like inner restlessness or an inability to sit still.
  • Insomnia or changes in sleep.
  • Anxiety, agitation, or increased activation.
  • Nausea, vomiting, or constipation.
  • Headache or dizziness.
  • Tremor or other extrapyramidal symptoms.
  • Fatigue or, in some people, increased daytime alertness.
  • Weight change and altered blood glucose or lipid measurements.

Akathisia is easy to mistake for worsening anxiety. A person may pace, shift position repeatedly, or describe a distressing urge to move. Increasing the dose without identifying akathisia can make the experience worse.

Record when restlessness begins in relation to each tablet. A pattern that starts after treatment initiation or dose escalation may help a clinician distinguish akathisia from an emerging manic or anxious state.

Movement-related reactions

Extrapyramidal symptoms include tremor, rigidity, slowed movement, muscle spasms, and restlessness. Tardive dyskinesia involves repetitive, involuntary movements that may affect the tongue, mouth, jaw, face, or limbs. It can appear after prolonged exposure to antipsychotics and may persist after treatment changes.

Urgent assessment is needed for severe muscle stiffness, high fever, confusion, heavy sweating, rapid heartbeat, or marked changes in consciousness. This cluster can indicate neuroleptic malignant syndrome, a rare but serious reaction associated with antipsychotic treatment.

Aripiprazole can also affect impulse control. New or unusually strong urges to gamble, spend money, eat excessively, or engage in risky sexual behaviour should be reported promptly. These urges can occur without a previous history of the behaviour.

Metabolic and cardiovascular monitoring

Hyperglycaemia, diabetes, lipid changes, and weight gain have been reported with antipsychotic treatment, although the extent of risk varies among medicines and individuals. Blood pressure, weight, waist measurement, glucose or HbA1c, and lipid levels may form part of follow-up.

Older adults with dementia-related psychosis have an increased risk of death when treated with antipsychotics. Abilify is not indicated for that treatment situation. People with a history of seizures, cardiovascular disease, fainting, diabetes, or swallowing difficulty require targeted risk assessment.

Report new involuntary mouth or tongue movements early. Waiting until movements become frequent can make it harder to distinguish tardive dyskinesia from temporary tremor or anxiety-related habits.

Mechanism of action

Aripiprazole acts mainly as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, while it blocks serotonin 5-HT2A receptors. This receptor activity helps regulate neurotransmission rather than suppressing dopamine activity in a uniform way.[1]

Dopamine helps control motivation, movement, reward, and the interpretation of sensory information. Excess dopamine signalling in some brain pathways is associated with hallucinations, delusions, and disorganised thinking. Reduced dopamine activity in other pathways can contribute to low motivation and impaired movement. Aripiprazole adjusts receptor stimulation according to the existing level of dopamine activity.

Neurotransmitter regulation in the central nervous system

Partial agonism means that aripiprazole activates a receptor, but less strongly than dopamine itself. Where dopamine activity is excessive, aripiprazole can reduce the strength of signalling. Where dopamine activity is low, it can provide a modest level of stimulation.

Serotonin receptor activity adds another layer to its pharmacology. This combination can support control of psychotic symptoms, manic symptoms, irritability, and mood instability. The response is gradual and depends on the diagnosis, treatment history, dose, and concurrent medicines.

Aripiprazole does not produce the same receptor profile as older dopamine-blocking antipsychotics. It may cause movement-related symptoms, though the risk pattern differs between individuals and can rise with higher exposure.

Common mistakes

Several practical errors can reduce benefit or create avoidable problems:

  • Stopping suddenly after early improvement.
  • Treating akathisia as ordinary anxiety and ignoring it.
  • Doubling a missed dose without checking the prescribed plan.
  • Starting fluoxetine, paroxetine, or carbamazepine without reporting it.
  • Assuming that less sedation means the medicine is not working.
  • Failing to report gambling, spending, eating, or sexual urges that feel unusually strong.
  • Using alcohol while still learning how the tablets affect alertness.
  • Assuming a long-acting injectable formulation can replace oral tablets immediately.
  • Measuring treatment success only by mood rather than psychosis, sleep, impulse control, and daily functioning.

A useful personal record includes the tablet time, sleep duration, restlessness, appetite, unusual urges, and major mood changes. This gives the treating clinician concrete information rather than a vague impression that the medicine feels “different.”

Comparison

Aripiprazole, risperidone, sertraline, fluoxetine, amitriptyline, and paroxetine do not perform the same therapeutic role. Aripiprazole and risperidone are antipsychotics. Sertraline, fluoxetine, and paroxetine are selective serotonin reuptake inhibitors, while amitriptyline is a tricyclic antidepressant.

Medicine or class Main pharmacology Clinical distinction
Aripiprazole Dopamine partial agonism and serotonin receptor activity Used for psychosis and bipolar I mania; akathisia can be prominent
Risperidone Stronger dopamine D2 and serotonin 5-HT2A antagonism Can cause prolactin elevation and movement symptoms
Sertraline, fluoxetine, paroxetine, amitriptyline Antidepressant mechanisms Used for selected depressive, anxiety, pain, or related conditions rather than acute psychosis

A clinician may favour aripiprazole when a person needs antipsychotic treatment and wishes to limit sedation or metabolic burden relative to some alternatives. That choice has a trade-off: restlessness, insomnia, activation, and impulse-control symptoms can be significant.

Risperidone may be selected when its clinical profile fits the person’s symptoms, yet prolactin-related effects can influence sexual function, menstruation, fertility, or breast symptoms. Antidepressants may help depression or anxiety but do not replace antipsychotic treatment for schizophrenia or acute bipolar mania.

What doctors say

Psychiatrists often judge Abilify by more than the first change in mood. They monitor psychotic symptoms, sleep, functioning, movement, weight, glucose, and behaviour over time. A person who feels more energetic after starting treatment may be improving, or may be developing activation or mania; the surrounding symptoms determine the interpretation.

Consistency matters because irregular exposure can make it difficult to distinguish treatment failure from missed doses. Clinicians also review whether the dose is too activating, whether akathisia is present, and whether another medicine is altering aripiprazole metabolism.

The EMA describes aripiprazole as a dopamine partial agonist with approved uses that include schizophrenia and manic episodes associated with bipolar I disorder.[4] Treatment decisions remain diagnosis-specific. The same tablet can be appropriate for one person and unsuitable for another because of seizure history, diabetes risk, drug interactions, or previous antipsychotic reactions.

What customers often ask

Can Abilify be used during pregnancy or breastfeeding?

Pregnancy and breastfeeding require an individual risk assessment because untreated schizophrenia or bipolar mania also carries medical risks. The FDA prescribing information (2023) describes neonatal adaptation and movement-related effects after exposure to antipsychotics during late pregnancy, while aripiprazole may reduce prolactin and affect milk production. Do not stop Abilify abruptly after becoming pregnant; the treating psychiatric and maternity teams should coordinate the plan. Breastfeeding decisions depend on the dose, infant health, feeding adequacy, and whether aripiprazole affects milk supply. Follow-up should include review of the infant and the parent's treatment response.

Can Abilify tablets be taken with food or on an empty stomach?

Aripiprazole tablets can generally be taken with or without food, which allows the person to choose a routine that supports regular use. A consistent time can reduce missed doses and makes changes in sleep or restlessness easier to identify. Alcohol may worsen dizziness or impaired judgement, even though it is not a food interaction. The EMA product information reviewed in 2024 continues to describe oral aripiprazole administration without a required meal-based schedule.

Which condition rules out Abilify treatment?

A previous serious allergic reaction to aripiprazole rules out further treatment with that medicine. Abilify is also not indicated for dementia-related psychosis in older adults because antipsychotic treatment in that setting carries increased mortality risk. A history of neuroleptic malignant syndrome, seizures, severe cardiovascular disease, or uncontrolled diabetes does not automatically produce the same rule for every person, but it requires a specific risk assessment. The TGA product information (2024) identifies these warnings and contraindication-related precautions in its aripiprazole documentation.

Which habits support treatment, and which can hinder the result?

Regular sleep, stable meal timing, moderate physical activity, and limiting alcohol can make changes in mood, appetite, alertness, and restlessness easier to recognise. Dehydration and excessive heat can worsen dizziness, while irregular tablet use can imitate treatment failure. Sudden changes in caffeine intake may also affect sleep and anxiety, although caffeine does not directly cancel aripiprazole’s receptor action. WHO guidance published in 2023 supports combining medicine review with attention to functioning, physical health, substance use, and social support in severe mental health conditions.[5]

How does Abilify differ from risperidone?

Abilify contains aripiprazole, which partially stimulates dopamine D2 receptors and modifies serotonin signalling. Risperidone has a different receptor profile, with stronger dopamine and serotonin antagonism. Aripiprazole may produce less prolactin elevation and less sedation for some people, while akathisia and activation can be more troublesome. Risperidone may be chosen when its symptom response fits the person, though prolactin changes and movement symptoms require monitoring; the APA guideline published in 2020 supports selecting antipsychotics through shared review of benefits, risks, and previous response.

How long does one Abilify dose keep working?

One oral dose contributes to aripiprazole exposure across the day, but symptom control depends on repeated dosing and the medicine’s long half-life. The clinical effect is not measured by a short-lived sensation after each tablet. Improvements in agitation or sleep may appear before full control of hallucinations, delusions, or relapse risk. The FDA label (2023) describes aripiprazole pharmacokinetics and its long elimination half-life, which means that missed doses and dose changes may influence the body for several days.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Comparison

Abilify Current

Active ingredient: Aripiprazole
10mg 15mg 20mg 5mg
From $ 147.74
pills
3.2 (5)

Solian

Active ingredient: Amisulpride
100mg 50mg
From $ 320.40
pills
3.8 (3)

How the medicines for Antipsychotics compare

Sources

  1. U.S. Food and Drug Administration (2023). Abilify (aripiprazole) Prescribing Information.
  2. American Psychiatric Association (2020). The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.
  3. Therapeutic Goods Administration (2024). Australian Product Information: aripiprazole.
  4. European Medicines Agency (2024). Abilify: European Public Assessment Report.
  5. World Health Organization (2023). Mental Health Gap Action Programme intervention guide: version 2.0.

How Buyers Rate Abilify

Based on 5 reviews

Robert, 64 Verified
Rating: 3.5 out of 5

I used Abilify tablets as part of treatment for schizophrenia for several months. The voices became less intrusive, and I was able to return to a steadier routine. The first weeks included restless legs and poor sleep, so the treatment plan needed adjustment.

Several months 8 Oct 2026
Graham, 54 Verified
Rating: 3.5 out of 5

My manic episode settled gradually rather than overnight. I noticed less racing speech and slept longer after the early treatment period. I still had some agitation and did not realise at first that it could be akathisia.

The early treatment period 21 Oct 2026
Lee N., 56 Verified
Rating: 3.5 out of 5

The tablets helped with suspicious thoughts, but I gained weight and my glucose results needed closer monitoring. The improvement was worthwhile, though the physical checks became part of my regular treatment.

Regular treatment 24 Oct 2026
Peter, 69 Verified
Rating: 3.5 out of 5

I had taken aripiprazole before and remembered feeling more alert than with another antipsychotic. This time dizziness was a problem when standing, especially on hot days, and the dose review helped.

A previous course and this treatment period 31 Oct 2026
Martin, 29 Verified
Rating: 2 out of 5

I noticed stronger urges to spend money after starting treatment. I had not connected the behaviour with Abilify until I mentioned it during review. The symptom was taken seriously, and the plan was changed.

After starting treatment 3 Nov 2026
Get our free app Shop faster and track your orders 3.8 · 491 reviews Install